NICE Technology Appraisals in the NHS in England: Area Team & CCG Level for MedTech & DebriSoft

The Innovation Scorecard aims to improve transparency within the NHS of what treatments recommended by NICE are available within Trusts and CCGs and at National and Area Team level. It is intended to support monitoring of compliance with NICE Technology Appraisal (TA) recommendations and to assist the NHS in the identification of variation, which can be explained, challenged or acted upon. It is not intended to be used for performance management.

The Innovation Health and Wealth Strategy set out plans to support development and adoption of innovation in the NHS. The National Institute for Health and Care Excellence (NICE) technology appraisal process assesses the clinical and cost effectiveness of new and existing medicines and treatments, and provides guidance on their use by the NHS.

There is no central collection of data which can directly support the assessment of uptake of NICE recommendations, nor is data on the number of patients treated available. Therefore this is an experimental publication, which makes use of data currently available from a range of sources, both from the NHS and the commercial sector. The HSCIC welcomes comments and suggestions from users to support future development of appropriate datasets and reporting.

《创新评分卡》旨在提升英国国家卫生服务系统（NHS）在推荐治疗方面的透明度，具体涵盖信托机构、临床 commissioning group（CCG）以及国家和地区团队层面所提供的治疗方案。该工具旨在辅助监测对NICE技术评估（TA）建议的遵守情况，并协助NHS识别可解释、挑战或采取行动的差异性。其目的并非用于绩效管理。
《创新健康与财富战略》概述了支持NHS内部创新发展和采纳的计划。英国国家卫生与临床优化研究所（NICE）的技术评估流程评估新药和现有药品及治疗方法的临床及成本效益，并为NHS提供使用指导。
目前尚无集中收集的数据能够直接支持对NICE推荐采纳情况的评估，亦无关于治疗患者数量的数据。因此，本出版物为一次实验性发布，利用了来自多个来源的数据，包括NHS和商业部门。健康服务委员会信息中心（HSCIC）欢迎用户提出意见和建议，以支持未来适当数据集和报告的发展。